Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.48 |
| ▸ | FPR1 | P21462 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4684601 | 0.87 | F10 (0.48) | F10FPR1FPR2 | |
| SCHEMBL4682683 | 0.82 | F10 (0.69) | F10FPR1FPR2 | |
| SCHEMBL4684652 | 0.77 | F10 (0.60) | F10FPR1FPR2 | |
| SCHEMBL24045761 | 0.77 | FPR2 (0.67) | F10FPR1FPR2 | |
| SCHEMBL6853157 | 0.76 | F10 (0.51) | F10FPR1FPR2 | |
| SCHEMBL4683375 | 0.75 | FPR2 (0.56) | F10FPR1FPR2 | |
| SCHEMBL4683093 | 0.75 | F10 (0.57) | F10FPR1FPR2 | |
| SCHEMBL24045869 | 0.75 | ALOX5AP (0.42) | F10FPR1FPR2 | |
| SCHEMBL4680127 | 0.75 | F10 (0.57) | F10FPR1FPR2 | |
| SCHEMBL24045750 | 0.75 | FPR2 (0.77) | F10FPR1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790845-B2 | HAVING AN ATTACHED NON-AROMATIC HETEROCYCLIC RING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-14 | — | — | US | disclosed |
| US-20030087909-A1 | Fused heterocyclic inhibitors of factor Xa | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-08 | — | — | US | disclosed |
| WO-2002080853-A2 | FUSED HETEROCYCLIC INHIBITORS OF FACTOR XA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087909-A1 | Fused heterocyclic inhibitors of factor Xa | TFPI, F11, F12 | F10 9/4885FPR1 964/4885FPR2 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.